Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Bidard, François-Clément; Cabel, Luc; Chevrier, Marion; Dalenc, Florence; Debled, Marc; Dubot, Coraline; Ferrero, Jean-Marc; Gonçalves, Anthony; Jacot, William; Jouannaud, Christelle,; Lemonnier, Jérôme; Lorgis, Veronique; Luporsi, Elisabeth; Lévy, Christelle; Mouret-Reynier, Marie-Ange; Pierga, Jean-Yves; Savignoni, Alexia; Tanguy, Marie-Laure; Trédan, Olivier; Vasseur, Antoine

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Authors: François-Clément Bidard
Luc Cabel
Marion Chevrier
Florence Dalenc
Marc Debled
Coraline Dubot
Jean-Marc Ferrero
Anthony Gonçalves
William Jacot
Christelle, Jouannaud
Jérôme Lemonnier
Veronique Lorgis
Elisabeth Luporsi
Christelle Lévy
Marie-Ange Mouret-Reynier
Jean-Yves Pierga
Alexia Savignoni
Marie-Laure Tanguy
Olivier Trédan
Antoine Vasseur
Publication date: 1 May 2020
Publisher: 'Springer Science and Business Media LLC'
Doi

Abstract

International audienceProof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757)